Latest Filings

Issuer Activity

Insider Overview :: Cardiome Pharma Corp. (T:COM) [?]
Business Focus: Biopharmaceuticals Share on StockTwits
This company is also listed in the United States as CRME on the NASDAQ. Click here to see if there are any SEC insider filings on insidertracking.com.
Recent Price for COM
CAD 8.24 +0.41 (+5.24%)
TSX Delayed 15 minutes
Apr 17 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
8.49 12.02 17.47 17,345 135.62
1-Day Low 52-Week Low Yield Avg. Volume  
7.75 1.83 0.0% 26,692  
Log in or sign up for a free account to add this stock to your watch list.

Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for COM within the last 6 months [?]
Amended Filing
As of 11:59pm ET April 19th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Mar 13/14 Mar 11/14 Fortress Investment Group LLC Control or Direction Common Shares 15 - Disposition under a prospectus -1,500,000 $10.00
Dec 31/13 Dec 30/13 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -1,000 $6.70
Dec 31/13 Dec 30/13 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -100 $6.70
Dec 31/13 Dec 30/13 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -100 $6.71
Dec 31/13 Dec 30/13 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -100 $6.73
Dec 31/13 Dec 30/13 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -1,100 $6.71
Dec 31/13 Dec 30/13 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -100 $6.70
Dec 31/13 Dec 30/13 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -1,500 $6.74
Dec 23/13 Dec 19/13 Rieder, Robert Direct Ownership Common Shares 10 - Acquisition in the public market 1,000 $7.02
Dec 8/13 Dec 3/13 Archibald, Jennifer Direct Ownership Options 52 - Expiration of options -1,100 $55.75
This company is also listed in the United States as CRME on the NASDAQ. Click here to see if there are any SEC insider filings on insidertracking.com.

Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for COM within the last 6 months [?]
Amended Filing
As of 11:59pm ET April 19th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Mar 13/14 Mar 11/14 Fortress Investment Group LLC Control or Direction Common Shares 15 - Disposition under a prospectus -1,500,000 $10.00
Mar 4/14 Mar 21/13 McMasters, David D. Direct Ownership Options 50 - Grant of options 60,000 $0.330
Mar 4/14 Dec 12/12 McMasters, David D. Direct Ownership Options 50 - Grant of options 175,000 $0.340
Mar 4/14 Nov 1/12 McMasters, David D. Direct Ownership Options 00 - Opening Balance-Initial SEDI Report    
Dec 31/13 Dec 30/13 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -1,000 $6.70
Dec 31/13 Dec 30/13 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -100 $6.70
Dec 31/13 Dec 30/13 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -100 $6.71
Dec 31/13 Dec 30/13 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -100 $6.73
Dec 31/13 Dec 30/13 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -1,100 $6.71
Dec 31/13 Dec 30/13 Rieder, Robert Direct Ownership Common Shares 10 - Disposition in the public market -100 $6.70
This company is also listed in the United States as CRME on the NASDAQ. Click here to see if there are any SEC insider filings on insidertracking.com.

Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for COM on April 17, 2014 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEDAR
Key People
Robert W. Rieder
Chairman of the Board
William L. Hunter
President, Chief Executive Officer, Director
Jennifer Archibald
Chief Financial Officer
Sheila M. Grant
Chief Operating Officer
Karim Lalji
Chief Commercial Officer
 
Company Contact
Address: 6TH FLOOR, 6190 AGRONOMY RD.
VANCOUVER BC V6T 1Z3
Tel: 1-604-6766993
Website: www.cardiome.com
IR: www.cardiome.com/investors
Business Overview
Cardiome Pharma Corp. (Cardiome) is a research-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of new therapies. It has one product, BRINAVESS, approved for marketing in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. The Company's clinical programs are also focused on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. Cardiome also has several pre-clinical projects directed at various therapeutic indications. The Company operates primarily in one business segment with all of its assets located in Canada and operations located in Canada, the United States, Switzerland and the United Kingdom. In March 2012, the Company announced that Merck & Co., Inc. (Merck) discontinued further development of vernakalant (oral). In November 2013, Cardiome Pharma Corp. completed the acquisition of Correvio LLC.
Financial Overview
For the fiscal year ended 31 December 2013, Cardiome Pharma Corp. revenues increased from $789K to $4.5M. Net income totaled $4.8M vs. loss of $18.3M. Revenues reflect Licensing and other fees increase of 8% to $499K. Net Income reflects Research and development decrease of 92% to $476K (expense), Amortization decrease of 47% to $649K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.49 to $0.37.
Employees: 75 as of Dec 31, 2013
Reporting Currency: U.S. Dollars
Enterprise value: $123.59M as of Dec 31, 2013
Annual revenue (TTM): $4.97M as of Dec 31, 2013
EBITDA (TTM): -$14.70M as of Dec 31, 2013
Net annual income (TTM): $5.26M as of Dec 31, 2013
Free cash flow (TTM): -$18.67M as of Dec 31, 2013
Net Debt Last Fiscal Year: N/A
Shares outstanding: 16,458,277 as of Mar 11, 2014
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
ProMetic Life Sciences (T:PLI)
Stem Cell Therapeutics (V:SSS)
 
Cardiome Pharma Corp. Insider Report Only $20.00